Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:AVTXNASDAQ:CNTBNASDAQ:CSCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.08-4.2%$1.05$0.80▼$3.08$44.37M-1.1518,615 shs2,745 shsAVTXAvalo Therapeutics$4.10-5.3%$4.60$3.39▼$16.00$44.40M0.757,537 shs89,023 shsCNTBConnect Biopharma$0.79+1.5%$0.75$0.51▼$2.07$43.98M-0.2756,595 shs28,306 shsCSCICOSCIENS Biopharma$3.69-0.9%$3.27$1.96▼$6.77$11.60M0.7412,014 shs3,251 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-4.17%+8.00%+0.93%+0.93%-46.53%AVTXAvalo Therapeutics-5.31%+3.80%-7.87%-47.16%-62.76%CNTBConnect Biopharma+1.46%+1.24%-1.06%-6.88%-53.44%CSCICOSCIENS Biopharma-0.91%+6.22%+4.12%+34.04%+368,599,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals1.9864 of 5 stars3.53.00.00.00.01.70.0AVTXAvalo Therapeutics2.9766 of 5 stars3.53.00.00.02.61.71.3CNTBConnect Biopharma2.272 of 5 stars3.53.00.00.00.62.50.6CSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50409.26% UpsideAVTXAvalo Therapeutics 3.00Buy$30.00631.71% UpsideCNTBConnect Biopharma 3.00Buy$8.00910.74% UpsideCSCICOSCIENS Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CSCI, ANEB, CNTB, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AAVTXAvalo Therapeutics$441K100.67N/AN/A$9.11 per share0.45CNTBConnect Biopharma$26.03M1.69N/AN/A$1.83 per share0.43CSCICOSCIENS Biopharma$9.03M1.28N/AN/A$14.99 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-119.54%-108.08%N/AAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)CNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/ACSCICOSCIENS Biopharma-$16.55M-$5.80N/A∞N/A-428.43%-95.93%-45.66%8/12/2025 (Estimated)Latest CSCI, ANEB, CNTB, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51AVTXAvalo TherapeuticsN/A1.421.42CNTBConnect BiopharmaN/A12.04N/ACSCICOSCIENS BiopharmaN/A3.463.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%AVTXAvalo Therapeutics87.06%CNTBConnect Biopharma58.72%CSCICOSCIENS Biopharma0.73%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%AVTXAvalo Therapeutics3.03%CNTBConnect Biopharma22.60%CSCICOSCIENS Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableCNTBConnect Biopharma11055.56 million42.77 millionOptionableCSCICOSCIENS Biopharma203.15 million3.77 millionN/ACSCI, ANEB, CNTB, and AVTX HeadlinesRecent News About These CompaniesCSCI COSCIENS Biopharma Inc.June 1, 2025 | seekingalpha.comCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of ShareholdersMay 30, 2025 | financialpost.comCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of ShareholdersMay 30, 2025 | finance.yahoo.comCOSCIENS Biopharma Inc. Announces Reconstitution of Board Following Resolution Agreement with GoodwoodMay 30, 2025 | quiverquant.comCosciens Biopharma announces receipt of Goodwood intended director nominationsMay 27, 2025 | finance.yahoo.comCOSCIENS Biopharma Receives Director Nominations Ahead of Shareholder MeetingMay 27, 2025 | tipranks.comCOSCIENS Biopharma Receives Director Nominations from GoodwoodMay 26, 2025 | tipranks.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for ...May 26, 2025 | gurufocus.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of ShareholdersMay 26, 2025 | financialpost.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for ...May 26, 2025 | gurufocus.comCOSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder MeetingMay 26, 2025 | quiverquant.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of ShareholdersMay 26, 2025 | globenewswire.comGoodwood to Nominate New Directors for COSCIENS Biopharma Inc.May 23, 2025 | finance.yahoo.comCOSCIENS Biopharma reports key corporate updatesMay 21, 2025 | uk.investing.comCOSCIENS Biopharma Completes Merger with Ceapro and Restructures GovernanceMay 20, 2025 | tipranks.comCosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)May 19, 2025 | theglobeandmail.comCosciens Biopharma Inc CSCIMay 16, 2025 | morningstar.comCOSCIENS Biopharma: Q1 Earnings SnapshotMay 13, 2025 | timesunion.comCOSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic ShiftsMay 13, 2025 | tipranks.comCOSCIENS Biopharma Reports Q1 2025 Results and Strategic UpdatesMay 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSCI, ANEB, CNTB, and AVTX Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.10 -0.03 (-2.40%) As of 06/6/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Avalo Therapeutics NASDAQ:AVTX$4.10 -0.23 (-5.31%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.08 -0.02 (-0.49%) As of 06/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Connect Biopharma NASDAQ:CNTB$0.79 +0.01 (+1.46%) Closing price 06/6/2025 03:59 PM EasternExtended Trading$0.78 -0.01 (-0.82%) As of 06/6/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.COSCIENS Biopharma NASDAQ:CSCI$3.69 -0.03 (-0.91%) As of 06/6/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
